Abbott Ups Vascular, Ophthalmic Focus With Two Acquisitions
This article was originally published in The Gray Sheet
Executive Summary
Abbott Laboratories announced July 15 it has entered into agreements to purchase stent manufacturer IDev Technologies and ophthalmic device company OptiMedica Corp. The acquisitions are intended to bolster the company’s medical device unit in the vascular and vision care businesses, respectively.
You may also be interested in...
People Briefs: Mercator, MITA And 23andMe
Drug-delivery firm Mercator MedSystems names a new CEO. Also, recent appointments at MITA and 23andMe.
Abbott Makes Good On IDev Buy With Supera Peripheral Stent Approval
Abbott announced PMA-approval of the Supera stent, which it gained in a $310 million acquisition of IDev Technologies last year. The approval gives Abbott a device specific for the superficial femoral artery, which the company says is one of the largest and fastest growing segments of the peripheral stent market.
Device/Diagnostics Quarterly Deal Statistics, Q3 2013
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.